Delenex Therapeutics AG

Delenex was a privately held, clinical stage biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics. Delenex aims at extending the benefits of proven antibody therapeutics to a much larger number of people suffering from a variety of oncological and dermatological diseases. Delenex'​ proprietary PENTRA®Bodies are small, highly potent and stable antibody fragments that are superior in penetrating tissues and in crossing barriers in the human body. The modular PENTRA®Body platform has proven ability to identify and rapidly generate best-in-class antibodies of various formats including single chain Fv fragments (scFv), IgG and bispecific antibodies. Delenex'validated humanized scFv have applications in immunotherapy in improving CAR-T cells and as TCR-like antibodies. Delenex was founded in September 2009 as a spin-off from ESBATech (now a Novartis company). In July 2016 Delenex was Acquired by Cell Medica.